semaglutide smpc Is Oral a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective Comparison of the injection‐site experience

GLP-1, a powerful physiological incretin: an update

Trials of orforglipron and lower-dose tirzepatide suggest that if and when these drugs are licensed, they could be used to maintain weight loss after higher-dose injectable incretin therapies 45

In December 2024, Gubra A/S , a company that specializes in pre-clinical contract research and peptide-based medication discovery for metabolic and fibrotic illnesses, has announced a collaboration with Amylyx Pharmaceuticals, Inc

PMID 2497921.

The WHO set out its thinking on the drugs for the first time in a special communication aimed at health professionals

Future research should concentrate on discovering optimum microbiome biomarkers for therapy selection and creating microbiome-targeted adjuvant medicines